Vascular Therapies Available in $25M Financing

Vascular Therapies

$25M was raised by Vascular Therapies, a Cresskill-based, NJ-based, clinical-stage biopharma firm.

This financing includes existing and new investors, as well as a Fortune 100 global healthcare provider.

Sirogen’s future development is the company’s goal.

Vascular Therapies is led by John McDermott, CEO, and Sriram Iyer MD, Chief Scientific Officer, Vascular Therapies. Vascular Therapies develops Sirogen, an exclusive sirolimus formulation to deliver local, perivascular drugs. This therapeutic approach aims to improve outcomes for patients with vascular disease and kidney problems. The primary endpoint of the Phase 3 clinical trial (ACCESS) was not met. However, a post-hoc analysis showed significantly improved AV fistula maturation and therapeutic durability in patients with end-stage renal disease aged 65 years and older.

The Sirogen™ drug development program has received Fast Track status from the FDA and sirolimus has Orphan Drug designation for dialysis vascular access indications in the U.S. and E.U. Sirogen™ is an investigational product and has not been determined to be safe and effective for any use.

 

Get latest news from African Startup ecosystem

Latest stories

You might also like...